Key Highlights
- QDENGA, a live attenuated vaccine covering all four dengue serotypes, received formal clearance from the Drug Controller General of India.
- Eligible recipients range from 4 to 60 years with no prerequisite sero‑typing before inoculation.
- Only two intramuscular injections are required, simplifying the vaccination schedule לחל7 years of safety data.
- The approval enhances India’s defensive strategy, complementing vector control and public awareness initiatives.
Detailed Insights
In the past two decades, India has experienced a staggering increase in dengue cases, surpassing 10‑fold the incidence reported in the 2000‑s. As of 2025, official counts exceeded 113,000, yet many experts suspect the true burden to be considerably higher. The introduction of QDENGA offers a robust preventive tool that fills the gap left by the absence of a specific antiviral treatment.
QDENGA’s clinical validation stemmed from Takeda’s extensive global programme involving over 28,000 subjects across 19 phase‑I, II and III studies. International data from the TIDES trial, encompassing more than 20,000 participants in eight countries, reported 80.2 % efficacy against laboratory‑confirmed infection one year post‑second dose and 90.4 % reduction in dengue‑related hospital admissions 18 monthsाइल. Sustained protection of 84.1 % against hospitalization over 4.5 years was observed, with safety and efficacy maintained through 7 years of follow‑up.
The World Health Organization prequalified the vaccine, eliminating the need for pre‑vaccination screening, and authorised its deployment in 43 countries, where over 32 million doses have already been delivered. National immunisation programmes in Brazil, Argentina, Colombia and Indonesia now include QDENGA in their public health strategy.
